| Autor: |
Rosa MN; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil., E Silva LRV; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil., Longato GB; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil.; Research Laboratory in Molecular Pharmacology and Bioactive Compounds, São Francisco University, Bragança Paulista 12916-900, Brazil., Evangelista AF; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil., Gomes INF; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil., Alves ALV; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil., de Oliveira BG; Petroleomic and Forensic Laboratory, Chemistry Department, Federal University of Espírito Santo, Vitória 29075-910, Brazil., Pinto FE; Petroleomic and Forensic Laboratory, Chemistry Department, Federal University of Espírito Santo, Vitória 29075-910, Brazil., Romão W; Petroleomic and Forensic Laboratory, Chemistry Department, Federal University of Espírito Santo, Vitória 29075-910, Brazil., de Rezende AR; Higher Institute of Education and Research of Ituiutaba, University of the State of Minas Gerais (UEMG), Ituiutaba 38302-192, Brazil., Araújo AAC; Higher Institute of Education and Research of Ituiutaba, University of the State of Minas Gerais (UEMG), Ituiutaba 38302-192, Brazil., Oliveira LSFM; Laboratory of Experimental Pathology, Federal University of São João del Rei-CCO/UFSJ, Divinópolis 35501-296, Brazil., de M Souza AA; Laboratory of Experimental Pathology, Federal University of São João del Rei-CCO/UFSJ, Divinópolis 35501-296, Brazil., Oliveira SC; Laboratory of Experimental Pathology, Federal University of São João del Rei-CCO/UFSJ, Divinópolis 35501-296, Brazil., de A Ribeiro RIM; Laboratory of Experimental Pathology, Federal University of São João del Rei-CCO/UFSJ, Divinópolis 35501-296, Brazil., Silva VAO; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil., Reis RM; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil.; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, 4710-057 Braga, Portugal. |
| Abstrakt: |
Cervical cancer is the third most common in Brazilian women. The chemotherapy used for the treatment of this disease can cause many side effects; then, to overcome this problem, new treatment options are necessary. Natural compounds represent one of the most promising sources for the development of new drugs. In this study, 13 different species of 6 families from the Brazilian Cerrado vegetation biome were screened against human cervical cancer cell lines (CCC). Some of these species were also evaluated in one normal keratinocyte cell line (HaCaT). The effect of crude extracts on cell viability was evaluated by a colorimetric method (MTS assay). Extracts from Annona crassiflora , Miconia albicans , Miconia chamissois , Stryphnodendron adstringens , Tapirira guianensis , Xylopia aromatica , and Achyrocline alata showed half-maximal inhibitory concentration (IC 50 ) values < 30 μg/mL for at least one CCC. A. crassiflora and S. adstringens extracts were selective for CCC. Mass spectrometry (Electrospray Ionization Fourier Transform Ion Cyclotron Resonance Mass Spectrometer (ESI FT-ICR MS)) of A. crassiflora identified fatty acids and flavonols as secondary compounds. One of the A. crassiflora fractions, 7C24 (from chloroform partition), increased H2AX phosphorylation (suggesting DNA damage), PARP cleavage, and cell cycle arrest in CCC. Kaempferol-3-O-rhamnoside and oleic acid were bioactive molecules identified in 7C24 fraction. These findings emphasize the importance of investigating bioactive molecules from natural sources for developing new anti-cancer drugs. |
